Skip to content

Earnings yield at other companies

Eli Lilly logo
Eli LillyLLY
3.1%+1.6pp
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-2.6%-0.9pp
Viking Therapeutics logo
Viking TherapeuticsVKTX
-12.6%-31.7pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
13.7%+9.2pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
72.9%+61.3pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
22.7%+15.1pp

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed November 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s earnings yield?
Gyre Therapeutics, Inc. (GYRE) reported earnings yield of 1% in Q3 2025.
How has Gyre Therapeutics, Inc.'s earnings yield changed year-over-year?
Gyre Therapeutics, Inc.'s earnings yield increased by 115.2% year-over-year, from -6.6% to 1%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.